-- 
Pfizer Deal Allows Dr. Reddy’s to Sell Depression Pill in U.S. From June 1

-- B y   A n o o p   A g r a w a l
-- 
2011-04-24T04:42:32Z

-- http://www.bloomberg.com/news/2011-04-24/pfizer-deal-allows-dr-reddy-s-to-sell-depression-pill-in-u-s-from-june-1.html
Dr. Reddy’s Laboratories Ltd.,
 India ’s second-largest drugmaker, will be allowed to sell a
generic version of Wyeth’s antidepressant drug starting June 1
following an agreement with the unit of  Pfizer Inc. (PFE)   Pfizer spokesman Christopher Loder, who confirmed the
agreement in an e-mail yesterday, declined to disclose financial
terms of the deal. Wyeth, a unit of the world’s largest
drugmaker, and Dr. Reddy’s reached a settlement to sell the drug
Effexor XR in the New Jersey Federal Court, Press Trust of India
reported on April 22.  Pfizer last year sold $1.7 billion of Effexor, which was
Wyeth’s best-selling antidepressant drug until 2008, before
cheaper generic version were released. The company has
previously settled patent-infringement suits regarding Effexor
it filed against  Teva Pharmaceutical Industries Ltd. (TEVA)  and Anchen
Pharmaceuticals Inc. and  Impax Laboratories Inc. (IPXL)   Dr. Reddy’s fell 1.2 percent to 1,656.8 rupees in Mumbai on
April 21. The shares have declined 0.4 percent this year
compared with a 1.6 percent advance in the MSCI AC Asia Pacific
excluding Japan Health Care Index.  Wockhardt Ltd. (WPL)  will also start sales of generic version of
the drug from June 1 after getting approval from the U.S. Food &
Drug Administration, the Mumbai-based company said in a
statement on April 19. Pfizer lost exclusivity for Effexor in
July 2010, the company said in its 2010  annual report .  Satish Reddy, Dr. Reddy’s managing director, didn’t respond
to a call made to his office today.  To contact the reporter on this story:
Anoop Agrawal in Mumbai at 
 aagrawal8@bloomberg.net   To contact the editor responsible for this story:
Paul Tighe at 
 ptighe@bloomberg.net  